Johnson & Johnson (JNJ)
| Previous close | 153.40 |
| Open | 153.10 |
| Bid | 152.04 x 800 |
| Ask | 152.07 x 800 |
| Day's range | 151.41 - 153.39 |
| 52-week range | 143.13 - 175.97 |
| Volume | |
| Avg. volume | 7,422,514 |
| Market cap | 366.417B |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | 22.62 |
| EPS (TTM) | 6.73 |
| Earnings date | 17 July 2024 |
| Forward dividend & yield | 4.96 (3.21%) |
| Ex-dividend date | 20 May 2024 |
| 1y target est | 172.72 |
GuruFocus.comJohnson & Johnson's Dividend Analysis
Johnson & Johnson (NYSE:JNJ) recently announced a dividend of $1.24 per share, payable on 2024-06-04, with the ex-dividend date set for 2024-05-20. Using the data from GuruFocus, let's delve into Johnson & Johnson's dividend performance and assess its sustainability. What Does Johnson & Johnson Do?
Simply Wall St.Johnson & Johnson Insiders Sell US$6.8m Of Stock, Possibly Signalling Caution
The fact that multiple Johnson & Johnson ( NYSE:JNJ ) insiders offloaded a considerable amount of shares over the past...
ReutersJ&J-backed startup Rapport files for US IPO
Rapport, which develops small molecule medicines for patients suffering from central nervous system disorders, is gearing up for a listing as the IPO market recovers from a slump amid increasing hopes of a soft landing for the economy. The company said it will be selling shares in the IPO, but did not disclose how many nor the price range. Rapport's net loss widened to $34.8 million in 2023 from $10.7 million a year earlier.
